Clinical Advisor7h
FDA Drug Approval Decisions Expected in April 2025
The FDA is expected to decide on treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine.
Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment
Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix"), today announced ...
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
Tiziana Life Sciences files IND application with FDA for ALS Phase 2 trial
Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...